tirzepatide surpass-4 versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Tirzepatide versus insulin glargine as – Tirzepatide for the Maintenance of

This aerophagia compounds the fermentation-related gas production

While the clinical evaluation of GLP-1MK-801 for weight loss awaits, efforts to broaden the scope of developing peptide-mediated targeting of ion channels are encouraged and should not be restricted to metabolic diseases

Not everyone responds equally to these treatments

Gala Health Best for: Patients who want a long-term tirzepatide plan layered onto womens-health-aware care, and who are comfortable committing for 12 months upfront

(2019) 6:e000993

Yet most primary care physicians (PCPs) are skeptical of telehealth platforms prescribing GLP-1s for weight loss